CIK 0001818794 · Large accelerated filer
Dyne Therapeutics, Inc.
Sign in to watch- Ticker
- DYN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364883909
- Phone
- (781) 786-8230
- Business address
- 1560 TRAPELO ROAD, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $40,000
- in 1 filing
- Open-market sales, last 90 days
- $247,777
- in 3 filings, $248K under 10b5-1 plans
Net −$207,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-06 | Scalzo Richard William SVP, Head of Finance & Admin. | Option exercise · Stock option (right to buy) | −6,552 | 28,394 | ||
| 2024-09-05 | Kersten Dirk Director | Sale 10b5-1 | −1,577 | $35.03 | $55K | 398,423 |
| 2024-09-04 | Cox John CEO & President | Purchase | +800 | $32.57 | $26K | 800 |
| 2024-09-04 | Cox John CEO & President | Purchase | +7,200 | $33.09 | $238K | 8,000 |
| 2024-09-04 | Cox John CEO & President | Purchase | +800 | $32.57 | $26K | 800 |
| 2024-09-04 | Cox John CEO & President | Purchase | +7,200 | $33.09 | $238K | 8,000 |
| 2024-09-04 | Cox John CEO & President | Purchase | +800 | $32.57 | $26K | 800 |
| 2024-09-04 | Cox John CEO & President | Purchase | +7,200 | $33.09 | $238K | 8,000 |
| 2024-09-04 | Cox John CEO & President | Purchase | +800 | $32.57 | $26K | 800 |
| 2024-09-04 | Cox John CEO & President | Purchase | +7,200 | $33.09 | $238K | 8,000 |
| 2024-09-03 | Kerr Douglas Chief Medical Officer | Grant or award | +47,500 | 47,500 | ||
| 2024-09-03 | Kerr Douglas Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +150,300 | 150,300 | ||
| 2024-09-03 | Friedl-Naderer Johanna Chief Commercial Officer | Grant or award | +58,400 | 58,400 | ||
| 2024-09-03 | Friedl-Naderer Johanna Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +185,300 | 185,300 | ||
| 2024-08-30 | Kersten Dirk Director | Sale 10b5-1 | −25,096 | $45.49 | $1.1M | 406,204 |
| 2024-08-30 | Kersten Dirk Director | Sale 10b5-1 | −6,204 | $46.01 | $285K | 400,000 |
| 2024-08-29 | Kersten Dirk Director | Sale 10b5-1 | −45,640 | $45.19 | $2.1M | 442,068 |
| 2024-08-29 | Kersten Dirk Director | Sale 10b5-1 | −10,768 | $45.81 | $493K | 431,300 |
| 2024-08-28 | Kersten Dirk Director | Sale 10b5-1 | −16,386 | $44.41 | $728K | 549,175 |
| 2024-08-28 | Kersten Dirk Director | Sale 10b5-1 | −61,467 | $44.94 | $2.8M | 487,708 |
Page 14 of 29 · 561 trades